Company announced the publication of clinical data from a Phase 1/2 trial of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkins Lymphoma (NHL) or Chrionic Lymphocytic Leukemia (CLL) previously exposed to rituximab. The data demonstrates single agent TG-1101 to be well tolerated with the most common adverse event observed […]
To All, Just looking for some feedback from everyone. I was considering purchasing more Aurinia to possibly take advantage of the short term catalyst which would be the upcoming release of secondary data from their Phase IIb Aura trial to help recoup losses from the FDA debacle of RGLS. Maybe some have already done so. […]
To All, I noticed that Michael Weiss, CEO of TG Therapeutics reduced his total share count considerably in 2016. He went from owning 4.5 million shares down to 1.1 million. Maybe he had to unload them by a certain date, I am not that familiar with shares owned by insiders. Just wanted to bring it […]
Take TG Therapeutics as an example, it has gone from 9.57 to 5.89 in a matter of 5,6,7 trading days scaring or forcing novice investors out of a position that will eventually recover.